Profile: Akari Therapeutics PLC (AKTX.OQ)
24 May 2019
Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, incorporated on October 7, 2004, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria (PNH), Guillain Barre syndrome (GBS) and atypical Hemolytic Uremic Syndrome (aHUS).
The Company's lead drug, Coversin, a complement inhibitor, acts on complement C5, preventing release of C5a and formation of C5b-9 (also known as the membrane attack complex (MAC)). Coversin is a recombinant small protein derived from a protein discovered in the saliva of the Ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response. The Company is conducting Phase Ib clinical trial of Coversin. The Company primarily focuses on rare and orphan diseases, including disease states spanning hematology, nephrology, transplantation, neurology and ophthalmology.
Akari Therapeutics PLC
75/76 Wimpole Street
LONDON NY W1G 9RS